Skip to main content
. 2024 Jun 4;7:685. doi: 10.1038/s42003-024-06297-0

Fig. 3. In vivo persistence of primary T cells derived from healthy donors.

Fig. 3

a Experimental scheme designed to assess the in vivo persistence of BBM-treated primary CD8+ T cells. b Gating strategy employed to determine the expression of CCR7 and CD45RA in the CD45+CD8β+ fractions. c Frequencies of injected CD45+CD8β+ cells in the spleen (left), peripheral blood (center), and bone marrow (right) on day 14. Each data point represents one injected mouse and its corresponding donors: circle; donor A, triangle; donor B, square; donor C. All error bars indicate SD. Statistical significance is denoted as follows: *p < 0.05; **p < 0.01; and ***p < 0.001 (unpaired t-test). d Representative flow cytometry plots of CCR7 and CD45RA in CD45+CD8β+ cells in the spleen samples.